Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon

Hepatology

Volumn 27, Issue 3, 1998, Pages 862-867

  Zarski, Jean Pierre ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; INDOMETACIN; KETOPROFEN; PARACETAMOL; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; TENOXICAM; VIRUS RNA;

ADULT; ARTICLE; ASTHENIA; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EPIGASTRIC PAIN; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHYROIDISM; LEUKOPENIA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PIROXICAM;

EID: 0031882995     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510270332     Document Type: Article

References (28)

1. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
2. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
3. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Metaanalysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. HEPATOLOGY 1996;24:778-789.
4. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non A, non B chronic hepatitis: a metaanalysis of randomized clinical trials. J Hepatol 1991;13:192-199.
5. Hannigan GE, Williams BRG. Signal transduction by interferon-a through arachidonic acid metabolism. Science 1991;251:204-207.
6. 2 is required for the formation of interferon-stimulated gene factor three. EMBO J 1995;15:1566-1571.
7. 2 production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal antiinflammatory drugs improve the therapeutic response to interferon? J Hepatol 1993;19:228-231.
8. Andreone P, Cursaro C, Gramenzi A, Buzzi A, Miniero R, Spovieri G, et al. Indomethacin enhances serum 2′5′-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis infection. J Hepatol 1994;21:984-988.
9. Andreone P, Cursaro C, Buzzi A, Miniero R, Sprovieri G, Gasbarrini G. Indomethacin enhances endogenous antiviral and increase response of patients with HBV or HCV CAH [Abstract]. Gastroenterology 1993;104:870A.
10. Andreone P, Gramenzi A, Cursaro C, Di Giammarino L, Fiorino S, Scrivano P, et al. A randomized controlled trial of IFN a + Ketoprofen or IFN a + Ribavirin in HCV chronic active hepatitis (CAH) non responder to IFN a alone. HEPATOLOGY 1995;22:119A.
11. Brooks PM, Day RO. Non steroidal anti-inflammatory drugs. Differences and similarities. N Engl J Med 1991;324:1716-1725.
12. Gerken G, Pontisso P, Roggendorf M, Rumi MG, Simmonds P, Trépo C, Zeuzem S, Colucci G. Clinical evaluation of a single reaction, diagnostic PCR assay for the detection of hepatitis C virus (HCV) RNA. J Hepatol 1996;24:33-37.
13. Roth WK, Lee JH, Ruster B, Zeuzem S. Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays. J Clin Microbiol 1996;34:261-264.
14. Young KKY, Resnick RM, Myers TW. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol 1993;31:882-886.
15. Bhattacherjee V, Prescott LE, Pike I. Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotype 1, 2, 3, 4, 5 and 6. J Gen Virol 1995;76:1737-1748.
16. Poitrine A, Chousterman S, Chousterman M, Naveau S, Thang MN, Chaput JC. Lack of in vivo activation of the interferon system in HBs Ag-positive chronic active hepatitis. HEPATOLOGY 1985;5:171-174.
17. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. 'Formulation and application of a numeral scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
18. Metavir . Intralobular and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. HEPATOLOGY 1994;20:15-20.
19. Baskin G. Interferon-signalling through arachidonic acid-dependent pathways: a clue to adjuvant therapy for chronic viral hepatitis? HEPATOLOGY 1991;14:392-394.
20. Di Costanzo GG, Ascione A, Lanza AG, Utech W, Capibianco G, Vacco C. Adjuvant therapy for interferon-resistant patients: do cycloxygenase inhibitors have any role ? A pilot study. J Hepatol 1995;23:359-360.
21. Andreone P, Cursaro C, Gramenzi A, Buzzii A, Miniero R, Sprovieri G, Gasbarri G. Alpha-interferon plus indomethacin combined therapy for non-responder patients with chronic hepatitis C [Abstract]. HEPATOLOGY 1993;18:659A.
22. Caldwell SH, Dickson RC, Driscoll C, Sue M, Yeaton P. A pilot studyusing piroxicam with interferon a 2b in the retreatment of refractory hepatitis C [Abstract]. Gastroenterology 1995;108:1043A.
23. Cakaloglu Y, Kaymakoglu S, Okten A, Badur S, Bestsik F, Erdem L, et al. Interferon-alpha 2a plus Tenoxicam treatment for chronic hepatitis B. International Symposium on Hepatology and Clinical Pharmacology Liver and Drugs. Bratislava/Slovatica 1994; Q-0479.
24. Pawlotsky JM, Hovanessian A, Roudot-Thoroval F, Lebon P, Robert N, Bouvier M, et al. Activity of the interferon-induced 2′,5′-oligoadenylate synthetase in patients with chronic hepatitis C. J Interfer Res 1995;15:857-862.
25. Giannelli G, Antonelli G, Fera G, Dianzani F, Schiraldi O. 2′,5′-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C. J Interferon Res 1993;13:57-60.
26. Merrit JA, Ball A, Sielaff KM, Meltzer DM, Borden EC. Modulation of 2′5′-Oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration. J Interferon Res 1992;12:7-16.
27. Martinot-Peignoux M, Marcellin P, Pouteau C, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. HEPATOLOGY 1995;22:1050-1056.
28. Henry DA, Lim LL-Y, Garcia-Rodriguez LA. Variability in risk of gastro-intestinal complications with individual non-steroidal antiinflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-1566.